NICE denies Cordis appeal
This article was originally published in The Gray Sheet
Executive Summary
The United Kingdom's National Institute for Health and Clinical Excellence denies Johnson & Johnson/Cordis' appeal of its Feb. 1 recommendation that the National Health Service only cover drug-eluting coronary stents if the device costs no more than £300 ($597) more than a comparable bare-metal stent (1"The Gray Sheet" Feb. 4, 2008, p. 10). 2In a decision released July 23, NICE's appeals panel, which met in April, discounts Cordis' arguments, concluding that NICE's recommendation does not exceed its legal powers or violate its established procedures and is consistent with the scientific evidence. There is no possibility of further appeal within NICE, but interested parties can seek permission form the High Court to apply for judicial review within three months, the panel writes. The denial of the appeal coincides with NICE's re-release of its 3final guidance on drug-eluting coronary stents outlining its recommendations
You may also be interested in...
U.K. Panel Says: Continue DES Use, But Limit Price Premium Over Bare Metal
The United Kingdom's National Institute of Health and Clinical Excellence has retreated from its August 2007 recommendation that the country's National Health Service stop paying for drug-eluting stents after being bombarded with criticism from interventional cardiologists and stent manufacturers
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.
‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach
In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.